News – BioTuesdays

Developments

Maxim survey finds two-thirds of respondents planning to attend JMP

A survey of 150 people to a recent Maxim Group survey about the upcoming J.P. Morgan Healthcare Conference found that 69% of respondents are planning to attend the conference in person, while 52% would choose in person...

September 26, 2022

Developments

Profound Medical presents durable and stable positive 4-year trends from TACT pivotal trial

An investigator for Profound Medical (NASDAQ:PROF; TSX:PRN) presented four-year follow-up data from the TACT clinical study with Profound’s TULSA-PRO device that continue to demonstrate durable and stable safety and...

September 26, 2022

Executive Moves

Paul Brennan steps down as CEO of NervGen

Paul Brennan Paul Brennan is stepping down as president, CEO and a director of NervGen Pharma (OTCQX:NGENF; TSXV:NGEN), effective immediately. The board appointed current executive chairman, Bill Radvak, as interim CEO...

September 23, 2022

Developments

OpSens SavvyWire in first U.S. procedure

Dr. Philippe Genereux, director of the Structural Heart Program at Morristown Medical Center in New Jersey, and his team, performed the first use of OpSens’ (TSX:OPS; OTCQX:OPSSF) SavvyWire in a transcatheter aortic...

September 23, 2022

Markets

Cantor sees Hepion Pharma potentially emerging from under the radar

In a new research report, Cantor Fitzgerald writes that Hepion Pharmaceuticals (NASDAQ:HEPA) is a company that has largely flown under the radar despite already achieving some early proof-of-concept evidence and having...

September 21, 2022

Developments

Novo Nordisk Foundation investing $200-million for first quantum computer for life sciences research

The Novo Nordisk Foundation has awarded a grant of $200-million to establish the first full-scale quantum computer for the development of new medicines as well as providing new insights into climate change and the green...

September 21, 2022

Developments

iBio acquires RubrYc Therapeutics’ AI drug discovery platform and pipeline

iBio (NYSEA:IBIO) closed the acquisition of substantially all of the assets of its partner, RubrYc Therapeutics, marking an important step in iBio’s mission to bring more, and better, immunotherapies to the...

September 21, 2022

Developments

MindMed collaborators begin dosing in Phase 1 trial of MDMA-like substances

The first patient has been dosed in a Phase 1 investigator-initiated study led by MindMed (NASDAQ:MNMD; NEO:MMED) collaborator Prof. Dr. Matthias Liechti at University Hospital Basel to evaluate the effects of MDMA-like...

September 20, 2022

Developments

Zucara secures Phase 2 funding for hypoglycemia trial

Closely-held Zucara Therapeutics’ positive proof-of-concept data has enabled the company to secure continued funding for a Phase 2 clinical study of ZT-01 to prevent hypoglycemia in people with Type 1 diabetes, which is...

September 19, 2022

Markets

WB ups Larimar to OP after Phase 2 clinical hold lifted

William Blair upgraded Larimar Therapeutics (NASDAQ:LRMR) to “outperform” after the FDA approved the company’s proposed Phase 2 study design for CTI-1601 in Friedreich’s ataxia (FA), enabling a return to clinical...

September 19, 2022

Developments

Profound Medical realigns commercial organization to support continued growth

Profound Medical (NASDAQ:PROF; TSX:PRN) has changed its management team and structure to further position the company for continued sales success and global growth. Abbey Goodman and Hartmut Warnken have been appointed...

September 15, 2022

Developments

FDA clears OpSens SavvyWire for transcatheter aortic valve replacement

OpSens (TSX:OPS; OTCQX:OPSSF) received 510(k) regulatory clearance from the FDA for SavvyWire, its new guidewire for transcatheter aortic valve replacement procedures, or TAVR. In a statement, Louis Laflamme, president...

September 15, 2022

Maxim survey finds two-thirds of respondents planning to attend JMP

Profound Medical presents durable and stable positive 4-year trends from TACT pivotal trial

Paul Brennan steps down as CEO of NervGen

OpSens SavvyWire in first U.S. procedure

Cantor sees Hepion Pharma potentially emerging from under the radar

Novo Nordisk Foundation investing $200-million for first quantum computer for life sciences research

iBio acquires RubrYc Therapeutics’ AI drug discovery platform and pipeline

MindMed collaborators begin dosing in Phase 1 trial of MDMA-like substances

Zucara secures Phase 2 funding for hypoglycemia trial

WB ups Larimar to OP after Phase 2 clinical hold lifted

Profound Medical realigns commercial organization to support continued growth

FDA clears OpSens SavvyWire for transcatheter aortic valve replacement

General

More